Analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to report earnings of $0.36 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Medidata Solutions’ earnings, with estimates ranging from $0.31 to $0.40. Medidata Solutions posted earnings per share of $0.40 during the same quarter last year, which indicates a negative year over year growth rate of 10%. The company is expected to announce its next earnings report on Thursday, April 18th.
On average, analysts expect that Medidata Solutions will report full year earnings of $1.80 per share for the current year, with EPS estimates ranging from $1.75 to $1.86. For the next financial year, analysts expect that the firm will report earnings of $2.17 per share, with EPS estimates ranging from $2.02 to $2.34. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Medidata Solutions.
Get Medidata Solutions alerts:
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Tuesday, February 12th. The company reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.08. The company had revenue of $167.19 million for the quarter, compared to analyst estimates of $168.08 million. Medidata Solutions had a return on equity of 10.03% and a net margin of 8.17%. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.41 earnings per share.
Several brokerages have issued reports on MDSO. Zacks Investment Research lowered Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Monday, January 28th. ValuEngine upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, BidaskClub upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a report on Wednesday, January 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $83.64.
MDSO traded up $1.14 during trading on Friday, hitting $75.45. The company’s stock had a trading volume of 437,727 shares, compared to its average volume of 555,810. Medidata Solutions has a twelve month low of $60.10 and a twelve month high of $88.87. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.52 and a current ratio of 2.71. The firm has a market cap of $4.62 billion, a PE ratio of 78.59, a price-to-earnings-growth ratio of 4.17 and a beta of 1.32.
In other Medidata Solutions news, Director Robert Taylor sold 2,120 shares of the company’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $64.70, for a total value of $137,164.00. Following the transaction, the director now directly owns 41,916 shares in the company, valued at approximately $2,711,965.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Rouven Bergmann sold 12,512 shares of the company’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $75.00, for a total value of $938,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 41,632 shares of company stock worth $3,126,704 in the last three months. 4.70% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the company. AMP Capital Investors Ltd increased its position in shares of Medidata Solutions by 16.8% during the 3rd quarter. AMP Capital Investors Ltd now owns 53,310 shares of the company’s stock valued at $3,933,000 after purchasing an additional 7,670 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Medidata Solutions during the 3rd quarter valued at about $229,000. Rice Hall James & Associates LLC increased its position in shares of Medidata Solutions by 106.7% during the 3rd quarter. Rice Hall James & Associates LLC now owns 251,973 shares of the company’s stock valued at $18,472,000 after purchasing an additional 130,070 shares during the last quarter. LPL Financial LLC increased its position in shares of Medidata Solutions by 25.2% during the 3rd quarter. LPL Financial LLC now owns 15,840 shares of the company’s stock valued at $1,161,000 after purchasing an additional 3,185 shares during the last quarter. Finally, American Capital Management Inc. increased its position in shares of Medidata Solutions by 3.3% during the 3rd quarter. American Capital Management Inc. now owns 669,649 shares of the company’s stock valued at $49,092,000 after purchasing an additional 21,136 shares during the last quarter.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Featured Article: What is a Call Option?
Get a free copy of the Zacks research report on Medidata Solutions (MDSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com